Remove 2015 Remove Confidentiality Remove Contracts Remove Settlement
article thumbnail

SEC Continues to Police Confidentiality Provisions for Theoretical Whistleblower Suppression

Trading Secrets

Morgan Securities, LLC (“JPMS”) for allegedly including overbroad release provisions in settlement agreements. And, as we previously blogged , the SEC historically had limited enforcement activity for Rule 21F-17(a), with roughly 14 enforcement actions between 2015 and 2021. with respect to such communications.”

article thumbnail

SEC Continues to Police Confidentiality Provisions for Theoretical Whistleblower Suppression

LexBlog IP

Morgan Securities, LLC (“JPMS”) for allegedly including overbroad release provisions in settlement agreements. And, as we previously blogged , the SEC historically had limited enforcement activity for Rule 21F-17(a), with roughly 14 enforcement actions between 2015 and 2021. with respect to such communications.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cox Sues Insurers for Failing to Cover Landmark Piracy Lawsuit

TorrentFreak

Without mentioning any figures, BMG said that it was “extremely happy” with the “substantial settlement.” Following the original verdict, before the eventual settlement, Cox informed its insurance companies Hiscox and ACE American Insurance of its claim. Beach of Contract? million in costs, Cox appealed the matter.

article thumbnail

Biosimilars 2020 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

For the first time since FDA licensed the first biosimilar, Sandoz’s Zarxio ® (filgrastim-sndz), in 2015, the United States saw a decrease in annual biosimilar approvals in 2020. Figure 1, below, provides a snapshot of FDA approval and biosimilar product launch trends from 2015 through 2020. 2015; resubmitted Feb. Conclusion.

article thumbnail

No "German injunction gap" expedition in Abbott v Dexcom global diabetes battle, as Mr Justice Mellor expresses "some regret"

The IPKat

The UK launch of the Freestyle Libre 3 is said to be confidential, but the G7 is intended to be launched this autumn 2021. This followed the end of the parties peace agreement provided for by a settlement agreement following the last bout of litigation. In Germany, Abbott has already launched the Freestyle Libre 3.

article thumbnail

Guest Post: Third-Party Litigation Funding: Disclosure to Courts, Congress, and the Executive

Patently-O

It generally amounts to more than 50% of the total settlement recovery, acknowledging, at least by basic math, that they are the primary beneficiary of the litigation.). self-reporting that “IP EDGE has returned over 3x the money it has invested in patents in the 2015-2021 time period with no down years”). [16]

article thumbnail

Biosimilars 2021 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

Figure 1 below provides an overview of biosimilar approvals by FDA and product launches in the United States from 2015 to 2021. No earlier than 2023 per settlement. No earlier than 2023 per settlement. No earlier than 2023 per settlement. . 2015; resubmitted Feb. No earlier than 2023 per settlement.